Suggested Remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for treating relapsed or refractory classical Hodgkin lymphoma
Status In progress
Process STA 2018
ID number 1557

Provisional Schedule

Expected publication 03 February 2021

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
11 June 2019 - 09 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 May 2019 In progress, Referred 17 October 2018

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance